Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases
This article was originally published in PharmAsia News
MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data
You may also be interested in...
With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.
Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..